Pharmacogenomics of Antiretrovirals

Author(s): Bernardino Roca.

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 3 , Issue 2 , 2008

Become EABM
Become Reviewer


HIV infection is a serious but treatable disease, yet current treatment is limited by development of resistance and high rates of adverse drug reactions. Antiretroviral therapy is especially suitable for pharmacogenomic investigation as both drug exposure and treatment response can be reliably measured. Increasing knowledge about genes implicated in pharmacokinetics, mode of action, efficacy, and toxicity of drugs has already provided relevant results for clinical practice, for example: • The strong association of the abacavir hypersensitivity reaction with HLA-B*5701 permits testing patients for the allele, and if present avoiding the drug and therefore preventing the reaction. • Persons with the allele CYP2B6*6 present higher efavirenz “area under the curve” and have increased risk of neuropsychological toxicity. Additional gene variants are being discovered that influence the action of antiretroviral drugs. And, moreover, it is expected that larger-scale comprehensive genome approaches will profoundly improve the landscape of knowledge of HIV therapy in the future. The present article shows some recent patents related to the treatment of viral infections.

Keywords: HIV, antiretrovirals, pharmacogenetics, pharmacogenomics

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2008
Page: [132 - 135]
Pages: 4
DOI: 10.2174/157489108784746650
Price: $58

Article Metrics

PDF: 2